Spain, Greece, the Czech Republic, Denmark and other international fertility hubs offer different advantages, but treatment eligibility, donor rules and reliable success data are more important than destination rankings
International fertility travel has developed into a specialised segment of medical tourism, with patients crossing borders for in vitro fertilisation (IVF), egg and sperm donation, fertility preservation and other assisted reproductive treatments. The choice of destination is influenced not only by treatment prices and clinical expertise but also by national legislation, access to donors, waiting times and the availability of services for different family structures.
Europe offers several established destinations, particularly Spain, Greece, the Czech Republic and Denmark. Their appeal differs considerably. Some attract patients seeking donor eggs or access to treatments unavailable at home, while others compete through comparatively affordable private clinics, international patient services and convenient travel connections. Portugal, Belgium and the United Kingdom also serve cross-border patients with particular legal or clinical requirements.
There is, however, no universally recognised ranking of the world's best IVF destinations. National treatment statistics are collected differently, patient populations vary, and published success rates are not always directly comparable. International comparisons of fertility treatment policies reveal substantial differences in access and regulation, while medical authorities advise prospective patients to examine overseas clinic standards, treatment risks and total costs before making a decision.
Southern Europe offers diverse treatment options
Spain is among Europe's most established destinations for international fertility patients. Barcelona, Madrid, Valencia and Alicante have developed concentrations of specialist reproductive medicine clinics offering IVF, intracytoplasmic sperm injection, donor programmes and fertility preservation.
Spain's appeal extends beyond treatment prices. Its legal framework permits assisted reproduction for single women and female same-sex couples, making it an option for patients whose access may be restricted elsewhere. Egg donation is also an important component of the country's fertility sector, although Spanish donor anonymity rules can be a significant consideration for families concerned about a child's future access to genetic origins.
Greece offers another important Mediterranean alternative, with fertility clinics in Athens, Thessaloniki and Crete serving patients from abroad. Its attraction includes donor treatment, international accessibility and a legal framework that accommodates some patients who encounter age-related or other restrictions in their home countries.
Research examining international fertility patients treated in Greece has identified dissatisfaction with services at home, perceived treatment outcomes and legal flexibility among motivations for travelling. Such findings provide insight into patient preferences but cannot establish that Greek clinics achieve better clinical outcomes than providers elsewhere.
Portugal adds a different dimension to the European market. Its donor-identification framework can appeal to patients who place particular importance on the future rights of donor-conceived children. Lisbon and Porto offer access to specialist fertility services, although treatment eligibility and donor availability must be confirmed individually.
Central Europe combines affordability with specialist care
The Czech Republic has developed a strong position in fertility travel, particularly through clinics in Prague and Brno. International patients are attracted by specialist reproductive medicine services, donor programmes and treatment prices that can be lower than those in parts of Western Europe.
However, eligibility is more restrictive than in Spain. Czech legislation requires a joint application from a woman and a man, and treatment is permitted only while the woman has not exceeded the statutory age limit of 49 years. These conditions exclude single women and female same-sex couples from treatment under the existing framework.
For eligible patients, the Czech Republic's location within Central Europe and its established international clinic sector make it a practical destination for repeated consultations and treatment visits.
Belgium is another established cross-border fertility destination, particularly for patients from neighbouring European countries. Brussels and other medical centres provide specialist reproductive services within a highly developed healthcare system. Its attraction is less closely associated with low-cost treatment than with access to particular services and proximity to major European population centres.
Denmark and Greece illustrate the importance of legal access
Denmark has become an important destination for patients seeking donor-assisted reproduction, including single women and female same-sex couples. Copenhagen and other Danish cities have specialist fertility clinics and access to established sperm donation services.
Danish rules nevertheless impose an important age restriction. Private fertility treatment is permitted only before a woman reaches 46 years of age. This makes Denmark unsuitable for some older patients, regardless of their willingness to pay privately.
Greece illustrates a contrasting approach. Its legislation allows medically assisted reproduction for women up to the age of 54, with additional medical assessments and approval from the national authority required for women over 50. The higher statutory threshold can attract patients who have reached treatment age limits elsewhere, although eligibility does not remove the medical risks associated with pregnancy at an advanced age.
These differences demonstrate why national legislation is a fundamental consideration in fertility tourism. The availability of IVF, donor eggs, donor sperm and other procedures cannot be assumed to be identical across destinations.
International alternatives extend beyond Europe
Outside Europe, the United States remains a significant destination for specialised reproductive medicine. Major centres offer complex fertility services, advanced laboratory techniques and treatment options governed by differing state and federal requirements.
The country also offers comparatively extensive public reporting of clinical outcomes. The US Centers for Disease Control and Prevention collects clinic-level assisted reproductive technology data, allowing patients to examine outcomes according to treatment characteristics. Nevertheless, age, infertility diagnosis and individual medical circumstances affect success, making simplistic clinic comparisons unreliable.
Mexico represents another option for international patients, particularly those travelling from North America. Private fertility services are available in major urban centres, while geographical proximity can make repeated visits more manageable for patients from the United States and Canada.
Regulatory scrutiny remains essential. Mexico's federal health regulator, COFEPRIS, requires healthcare establishments performing relevant assisted reproductive procedures to hold appropriate sanitary authorisation. Prospective patients should verify the licensing status and clinical responsibilities of individual providers rather than relying on marketing claims.
Other countries, including Türkiye and destinations in Asia, also have established fertility treatment sectors. Their suitability for international patients depends heavily on national rules governing marriage, donor gametes, eligibility and permitted procedures. The presence of sophisticated private hospitals does not necessarily mean that every reproductive treatment is legally available to foreign visitors.
Treatment outcomes matter more than headline prices
Cost remains an important motivation for fertility travel, but comparing advertised IVF package prices can be misleading. Some quotations exclude medication, diagnostic tests, embryo freezing, storage, donor-related services or additional treatment cycles.
Travel expenses also require careful planning. Ovarian stimulation and monitoring may involve several appointments, while egg retrieval, fertilisation and embryo transfer must follow medical schedules. Some patients can complete preliminary examinations at home, but the feasibility of shared care depends on coordination between clinics.
The most consequential comparison concerns clinical outcomes. Pregnancy rates, live-birth rates and cumulative outcomes across multiple cycles measure different things. Results may also be reported per embryo transfer, egg retrieval or treatment cycle, producing figures that cannot be compared without examining their definitions.
Britain's Human Fertilisation and Embryology Authority cautions against interpreting unusually high success rates without understanding the patients included in the statistics. It also identifies multiple pregnancies as a major safety concern and encourages patients to investigate embryo-transfer policies, donor screening, legal safeguards and complaint procedures.
Fertility tourism therefore differs from many other forms of elective medical travel. Treatment decisions may have consequences extending well beyond the visit itself, particularly where donor identity, genetic parentage, embryo storage and the legal recognition of parenthood are concerned.
For international patients, Spain, Greece, the Czech Republic and Denmark illustrate how different combinations of clinical services, legal access and travel infrastructure can shape destination choice. Portugal, Belgium, the United States and Mexico provide further alternatives for particular patient groups.
The strongest destinations are not necessarily those advertising the lowest prices or highest success rates. Their long-term competitiveness will depend on transparent outcome reporting, appropriate regulation, continuity of care and the ability to provide reliable information to patients navigating complex medical and legal decisions across borders.
Image Credit: © AI generated illustration
